US OptionsDetailed Quotes
PFE250103P20000
- 0.01
- 0.000.00%
15min DelayTrading Jan 3 16:00 ET
0.00High0.00Low
0.00Open0.01Pre Close0 Volume37 Open Interest20.00Strike Price0.00Turnover0.00%IV25.87%PremiumJan 3, 2025Expiry Date0.00Intrinsic Value100Multiplier-3DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2696.50Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Pfizer Stock Discussion
Sign in to post a comment
$Pfizer (PFE.US)$ i think not far from 28 le, look at moderna..
1
entire market is red except healthcare $Pfizer (PFE.US)$ $Moderna (MRNA.US)$
is there anything that ring the bell ?
is there anything that ring the bell ?
1
$Pfizer (PFE.US)$
The chart looks good with RSI turning up and stock becoming bullish. Next resistance is 27.56. Once it breaks the resistance, next hit point will be 27.70.
The chart looks good with RSI turning up and stock becoming bullish. Next resistance is 27.56. Once it breaks the resistance, next hit point will be 27.70.
$Pfizer (PFE.US)$
Moderna stock jumped early Tuesday after the first bird flu death was reported in the U.S.
Shares were up 3.8% to $44.23 in premarket trading, after initially rising as much as 6%. Futures tracking the benchmark S&P 500 index traded largely flat.
Moderna is one of a few drugmakers currently developing a vaccine for the H5N1 bird flu, which is spreading rapidly through farms and wild animals in North America.
As of Jan. 6, there have been 66 confirmed human cases of H5N1 bird ...
Moderna stock jumped early Tuesday after the first bird flu death was reported in the U.S.
Shares were up 3.8% to $44.23 in premarket trading, after initially rising as much as 6%. Futures tracking the benchmark S&P 500 index traded largely flat.
Moderna is one of a few drugmakers currently developing a vaccine for the H5N1 bird flu, which is spreading rapidly through farms and wild animals in North America.
As of Jan. 6, there have been 66 confirmed human cases of H5N1 bird ...
4
$Pfizer (PFE.US)$
The stock has broken the 26.83 resistance. Next hit point will be 27.15.
The stock has broken the 26.83 resistance. Next hit point will be 27.15.
5
2
$Pfizer (PFE.US)$
Malaysia saw 327 cases of human metapneumovirus (HMPV) infections in 2024, a 45 per cent rise from the 225 cases in 2023.
The Health Ministry said on Jan 4 that HMPV – a respiratory tract infection caused by a virus in the Pneumoviridae family – is not a new disease.
Those with HMPV typically experience symptoms similar to those of a common cold, but in more severe cases the symptoms can progress to bronchitis or pneumonia.
Malaysia recorded 327 HMPV cases in 2024; Health Ministry urges public to remain vigilant | The Straits Times
Malaysia saw 327 cases of human metapneumovirus (HMPV) infections in 2024, a 45 per cent rise from the 225 cases in 2023.
The Health Ministry said on Jan 4 that HMPV – a respiratory tract infection caused by a virus in the Pneumoviridae family – is not a new disease.
Those with HMPV typically experience symptoms similar to those of a common cold, but in more severe cases the symptoms can progress to bronchitis or pneumonia.
Malaysia recorded 327 HMPV cases in 2024; Health Ministry urges public to remain vigilant | The Straits Times
2
2
$Pfizer (PFE.US)$
Updates with response from Bristol-Myers Squibb in the fourth and fifth paragraphs.
Drugmakers including Pfizer (PFE), Bristol-Myers Squibb (BMY) and Sanofi (SNY) plan to raise US list prices on at least 250 branded medications, including COVID-19 treatments, cancer cell therapies and vaccines, at the start of 2025, Reuters reported Tuesday, citing data from the healthcare research firm 3 Axis Advisors.
Most of the price hikes are below 10% and are to list prices, which do not i...
Updates with response from Bristol-Myers Squibb in the fourth and fifth paragraphs.
Drugmakers including Pfizer (PFE), Bristol-Myers Squibb (BMY) and Sanofi (SNY) plan to raise US list prices on at least 250 branded medications, including COVID-19 treatments, cancer cell therapies and vaccines, at the start of 2025, Reuters reported Tuesday, citing data from the healthcare research firm 3 Axis Advisors.
Most of the price hikes are below 10% and are to list prices, which do not i...
2
4
$Pfizer (PFE.US)$ i bought 100 shares
2
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
No comment yet
Deep Sea : Yup. Saw it. MRNA up more than 10%.